BMO Capital raised the firm’s price target on Gilead to $94 from $85 and keeps an Outperform rating on the shares as part of a broader research note previewing Q3 results in BioPharma. Gilead is executing on its turnaround story following setbacks in oncology with a string of HIV wins, while the approval of recently-acquired Seladelpar – now Livdelzi – are buoying investor sentiment, the analyst tells investors in a research note. The recent wins are likely enough to drive sentiment in the near term, with additional upside potentially coming from the Phase 2 iMMagine-1 data expected in Q4, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead initiated with an Outperform at Bernstein
- JMP Securities healthcare analysts hold an analyst/industry conference call
- Gilead price target raised to $100 from $95 at JPMorgan
- Microsoft, Qualcomm downgraded: Wall Street’s top analyst calls
- Arcus Biosciences initiated with an Overweight at Wells Fargo